JenaValve wins FDA approval for Trilogy valve in severe AR

CURRENT FULL VERSION: JenaValve has secured FDA premarket approval for its Trilogy Transcatheter Heart Valve System, clearing the device for patients with symptomatic, severe native aortic valve regurgitation who are at high or greater risk for surgery. The March 17, 2026 decision is notable because it creates a labeled transcatheter treatment option for aortic regurgitation, an area where clinicians have often had to rely on surgery or off-label device use. JenaValve has said it plans an immediate commercial launch through participating study sites, followed by expansion to hospitals across the US. (accessdata.fda.gov; PharmaShots)

The background here matters. Transcatheter aortic valve replacement has become well established in aortic stenosis, but pure native aortic regurgitation has been harder to treat because the lack of calcification can make standard valves less stable. JenaValve’s Trilogy system was designed to address that problem by clipping onto the native leaflets rather than relying only on annular calcification for anchoring. Company materials describe radiopaque locators that attach directly to the native aortic leaflets without calcification, with the goal of stable implantation, precise alignment, reduced paravalvular regurgitation, and preserved future coronary access through an open-cell nitinol frame. FDA’s approval reflects that narrower design logic: the label covers severe native tricuspid aortic regurgitation in patients with high surgical risk, and it excludes disease caused by acute endocarditis, rheumatic heart disease, or acute aortic dissection. (accessdata.fda.gov; PharmaShots)

The pivotal evidence came from the ALIGN-AR investigational device exemption study. FDA’s Summary of Safety and Effectiveness Data says the primary effectiveness endpoint was met, with 11 deaths among 177 evaluable patients at one year, or 6.2%, below the prespecified 25% performance goal. In the premarket cohort, the 30-day composite safety endpoint occurred in 26.7% of patients, technical success reached 95.0%, and 30-day mortality was 2.2%. The most common early event was new permanent pacemaker implantation, affecting 24.0% of patients without a prior pacemaker. (accessdata.fda.gov)

Broader ALIGN-AR reporting has painted a similar picture. The American College of Cardiology’s coverage of the trial presentation said the study enrolled 500 patients between 2018 and 2024 for the premarket and continued-access cohorts, found 91.9% one-year survival in the reported analysis, and showed low rates of residual regurgitation. ACC’s later expert analysis, citing the 2025 Lancet publication, described 700 patients enrolled across 30 U.S. centers through July 2025, with 30-day pacemaker rates declining over time as operators gained experience and patient selection improved. That suggests at least part of the early safety burden may be modifiable with technique, though that’s an inference from evolving cohort performance rather than a randomized comparison. (acc.org)

Expert commentary has been measured rather than celebratory. ACC’s expert analysis called Trilogy “a promising therapeutic option” for high-risk patients with native aortic regurgitation, while also underscoring the trial’s limitations, especially its single-arm design and the still-elevated pacemaker rate. Trial investigator Raj Makkar said the findings marked progress over the historical limitations of off-label TAVR in aortic regurgitation, particularly around valve function and leakage. (acc.org)

Why it matters: For veterinary professionals, especially those following translational cardiology and device regulation, the approval is a useful case study in how FDA is handling niche structural heart indications: targeted label, tightly defined population, and mandatory postmarket follow-up. It also shows how a device can succeed by solving a specific anatomical problem rather than competing head-on in a broad category. In Trilogy’s case, that means a leaflet-anchoring approach built for noncalcified native aortic regurgitation, with design features meant to improve positioning and limit paravalvular leak while preserving coronary access. At the same time, the approval reinforces a familiar lesson from interventional medicine: a new option can be clinically meaningful even when it carries important procedural risks that require specialized training, careful case selection, and long-term surveillance. (accessdata.fda.gov; PharmaShots)

The label and FDA materials also make clear this won’t be a plug-and-play technology. The device should be used by teams experienced in TAVR, and the safety profile has not been established in several higher-risk subgroups, including patients with bicuspid or quadricuspid anatomy, prior prosthetic aortic valves, severe pulmonary hypertension, very low left ventricular ejection fraction, major aortic disease, or severe renal insufficiency. Those restrictions are likely to shape uptake just as much as the approval itself. (jenavalve.com)

What to watch: FDA has already listed two post-approval studies, one for continued follow-up of the premarket cohort and another for registry-based real-world surveillance, including patients entered into the STS/ACC Transcatheter Valve Therapy Registry during the first two years after approval or the first 2,000 treated patients, whichever is greater. Clinicians will also be watching whether JenaValve can reduce pacemaker rates further, how quickly the initial study-site launch translates into broader hospital adoption, and whether a planned randomized trial against surgery moves ahead. (accessdata.fda.gov; PharmaShots)